Gut Microbiome

Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization.

TL;DR

Early-life transmission of aromatic lactate-producing bifidobacteria, facilitated by vaginal delivery, older siblings, and exclusive breastfeeding, increases gut aromatic lactate levels and is inversely associated with food allergen-specific IgE development and atopic dermatitis, with 4-hydroxy-phenyllactate mediating this effect by inhibiting IgE but not IgG production.

Key Findings

Early-life colonization by aromatic lactate-producing bifidobacteria was inversely associated with food allergen-specific IgE development up to 5 years of age.

  • 147 children were followed from birth to 5 years of age
  • The microbiota-metabolite signature of aromatic lactate-producing bifidobacteria and elevated aromatic lactates was inversely associated with development of food allergen-specific IgE until 5 years
  • The study used a longitudinal birth cohort design tracking microbial colonization and immune outcomes over 5 years

Aromatic lactate-producing bifidobacteria colonization was associated with reduced atopic dermatitis at 2 years of age.

  • The microbiota-metabolite signature was inversely associated with atopic dermatitis at 2 years
  • The association was observed in the same 147-child cohort followed from birth
  • Atopic dermatitis was assessed as a clinical outcome alongside immunological markers

Three early-life practices facilitated transmission of aromatic lactate-producing bifidobacteria: vaginal delivery, exposure to older siblings, and exclusive breastfeeding for the first 2 months.

  • Vaginal delivery, exposure to older siblings, and exclusive breastfeeding for the first 2 months were all identified as transmission-facilitating factors
  • These practices were associated with increased levels of aromatic lactates in the infant gut
  • These findings link common perinatal and feeding practices to the establishment of a protective microbiota-metabolite signature

4-hydroxy-phenyllactate (4-HPL) specifically inhibited IgE production but not IgG production in ex vivo human immune cell cultures.

  • 4-hydroxy-phenyllactate was identified as the mediator of the observed protective effect
  • The inhibitory effect was selective for IgE and did not extend to IgG production
  • The finding was demonstrated using ex vivo human immune cell cultures
  • This selective inhibition suggests a mechanism by which aromatic lactates could reduce allergic sensitization without broadly suppressing humoral immunity

The study defines an early-life microbiota-metabolite-immune axis linking microbial transmission and feeding practices with reduced allergic sensitization.

  • The axis connects aromatic lactate-producing bifidobacteria colonization, gut aromatic lactate levels, and downstream immune outcomes including IgE and atopic dermatitis
  • 4-hydroxy-phenyllactate was identified as a key mediator within this axis
  • The axis was characterized in 147 children followed longitudinally from birth to 5 years
  • The findings integrate microbiological, metabolomic, and immunological data to describe a mechanistic pathway

Early microbial exposures that shape immune development and allergy risk operate through specific microbial taxa producing bioactive metabolites.

  • Food allergen sensitization, reflected by food allergen-specific IgE, is described as an early indication of impaired immune tolerance
  • The study identifies aromatic lactate-producing bifidobacteria as a specific functional group relevant to allergy protection
  • The role of gut microbiota metabolites, particularly aromatic lactates, is highlighted as a mechanistic link between microbial colonization and immune outcomes

Have a question about this study?

Citation

Myers P, Dehli R, Mie A, Moll J, Roager H, Eriksen C, et al.. (2026). Early-life colonization by aromatic-lactate-producing bifidobacteria lowers the risk of allergic sensitization.. Nature microbiology. https://doi.org/10.1038/s41564-025-02244-9